The transformation of B cells by Epstein-Barr virus (EBV), into lymphoblastoid cell lines (LCLs) results in the upregulation of STAT1, a key transcription factor in the interferon signalling pathway. Although the mechanism of EBV induction of STAT1 protein expression has been intensively studied, there has been little investigation into the function of STAT1 in EBV-transformed LCLs. In this study, we have implemented a novel strategy to investigate the functional role of STAT1 through the introduction of the simian virus 5 (SV5) V-protein into LCLs by retroviral gene transfer. The V-protein is a virally evolved STAT1 inhibitor that specifically targets STAT1 for proteasomal degradation. Using this in vitro model, we have shown that major histocompatibility complex (MHC) class I and class II molecules are downregulated at the cell surface following a reduction in STAT1 protein expression. With regards to MHC class I, the impairment of the antigen processing machinery renders the cells less recognized by the host EBV-specific immunosurveillance. In addition, downregulation of STAT1 increases the expression of LMP2A and lytic cycle antigens and results in a higher proportion of cells entering the lytic cycle. These results suggest that STAT1 is involved in maintaining the latency III viral program observed in transformed B cells and regulating immunorecognition by EBV-specific T cells.
INTRODUCTION
Epstein-Barr virus (EBV) is a human gammaherpesvirus which has a potent B cell transforming function. This growth-transforming capability is suppressed in immunocompetent hosts by cellular immune responses including EBV-specific cytotoxic T cells (CTLs) which recognize viral peptides presented on the surface of transformed B cells by major histocompatibility complex (MHC) class I molecules Rickinson & Moss, 1997) . However, EBV infection is associated with the pathology of several B cell malignancies, such as Burkitt's lymphoma (BL) and Hodgkin's lymphoma, and can lead to the development of EBV-associated post-transplant lymphoproliferative disease (PTLD) in immunocompromised patients . Impairment of the T-cell repertoire enables EBV to transform B cells into PTLD lesions. Transformation results in the establishment of a latency III viral program and the expression of the full panel of EBV latent genes. These include the EBV nuclear antigens EBNA1, -2, -3A, -3B, -3C and -LP and the latent membrane proteins LMP1, -2A and -2B Young et al., 1989) . Latency III is also observed in lymphoblastoid cell lines (LCLs), which are generated following in vitro transformation of primary B cells by EBV and represent an in vitro model for PTLD . The expression of all six EBNAs is driven from either the BamHI W promoter (Wp) or C promoter (Cp) as a long Wp/Cpinitiated transcript, which is differentially spliced into each individual EBNA Sample et al., 1986; Woisetschlaeger et al., 1989) , and all three LMPs are transcribed from EBNA2-responsive promoters (Abbot et al., 1990; Fåhraeus et al., 1990; Young et al., 1991; Zimber-Strobl et al., 1991) . These viral gene products act to maintain the latency III phenotype although spontaneous EBV replication, typically in less than 5 % of cells, can be observed in LCLs and similarly in PTLD lesions (Katz & Saini, 1992; Rea et al., 1994) . The transforming abilities of EBV are crucially dependent on EBNA2 and LMP1 (Abbot et al., 1990; Kaye et al., 1993; Kilger et al., 1998; Tanner & Alfieri, 2001) . LMP1 is transactivated by EBNA2 and mimics a constitutively activated CD40 receptor (Gires et al., 1997; to modulate the expression of an array of host proteins including MHC class I molecules . LMP1 has been shown to induce the expression of signal transducer and activator of transcription 1 (STAT1) (Richardson et al., 2003; Zhang et al., 2004) , which is an integral transcription factor in interferon (IFN) signalling pathways. STAT1 activation involves a phosphorylation cascade which enables STAT1 to bind to specific DNA sequences in the promoters of IFN-responsive genes and activate transcription (Darnell et al., 1994) . The induction of STAT1 expression by LMP1 involves two C-terminal activating regions (CTAR-1 and CTAR-2) located on the cytoplasmic carboxy tail of LMP1 (Huen et al., 1995; Richardson et al., 2003; Zhang et al., 2004) and results in the formation of a unique STAT1 DNA-binding complex (McLaren et al., 2007) . Although the mechanism of EBV induction of STAT1 protein expression is known, there has been little investigation into the function of STAT1 in EBV-transformed LCLs. Methods that have been employed to inhibit STAT1 activity in EBV-transformed LCLs include using fludarabine, a nucleoside analogue used in the treatment of haematological malignancies (Plunkett et al., 1993) , which has demonstrated inhibitory effects on STAT1 signalling in peripheral blood mononuclear cells and EBV-transformed LCLs (Fagard et al., 2002; Frank et al., 1999) . However, given that fludarabine can inhibit DNA and RNA synthesis and that high concentrations were required over a long time period in order to inhibit STAT1 (Fagard et al., 2002) , it is likely that these effects were not STAT1-specific. Overexpression of STAT1b, a naturally inactive isoform of STAT1, has also been used to inhibit STAT1 activity in LCLs and indicated that STAT1 may be involved in CD95-mediated apoptosis (Le Clorennec et al., 2006) .
In this study, we implemented a novel strategy to investigate the functional role of STAT1 in EBV-transformed B cells through the introduction of the simian virus 5 (SV5) V-protein by retroviral gene transfer. SV5 belongs to a family of paramyxoviruses which encode viral Vproteins that directly interact with STAT proteins (Horvath, 2004) . The SV5 V-protein represents a virally evolved STAT1 inhibitor that solely targets STAT1 for proteasomal degradation (Didcock et al., 1999; Precious et al., 2005) .
Using this in vitro model, we have shown that MHC class I and class II molecules are downregulated at the cell surface following a reduction in STAT1 protein expression. With regards to MHC class I, the impairment of the antigen processing machinery caused by STAT1 downregulation reduces the recognition of these cells by EBV-specific CTLs. In addition, the expression of the viral gene LMP2A and lytic cycle antigens is increased when STAT1 protein expression is diminished and a higher proportion of cells spontaneously enter the lytic cycle. These results demonstrate that STAT1 is involved in host and viral gene expression and plays a role in maintaining the latency III viral program observed in EBV-transformed B cells and their recognition by EBV-specific CD8 + T cells.
METHODS
Cell culture. IARC-171-LCL (Rowe et al., 1989) and IB4-LCL (King et al., 1980) have been described previously and MR-LCL, EW-LCL and RS-LCL were derived by in vitro transformation of primary B cells with EBV strain B95.8. Several different EBV-positive lines were used as standard controls for analysis of EBV mRNA transcripts (Bell et al., 2006) . These were X50-7 LCL (Wilson & Miller, 1979) , Oku-LCL (Kelly et al., 2002) , Rael-BL (Rooney et al., 1986) and Chege-LCL (Habeshaw et al., 1999) . The AKBM cell line has been described previously (Ressing et al., 2005) . All cell lines were cultured in RPMI 1640 medium supplemented with 10 % fetal calf serum, 2 mM Lglutamine and antibiotics (200 U penicillin ml 21 and 200 mg streptomycin ml 21 ), and were maintained at 37 uC in a 5 % CO 2 humidified incubator.
Retroviral constructs and infection of EBV-transformed LCLs.
The SV5 V-protein gene was cloned from pGEM3Z-SV5 V-protein (Precious et al., 1995;  kindly provided by Professor Rick Randall, University of St Andrews, UK) into the EcoRI-SalI site of pBabe-puro (Morgenstern & Land, 1990) to generate pBabe-puro SV5 V-protein.
Retrovirus was generated following packaging of the pBabe-puro SV5 V-protein vector into the y-crip packaging cell line (Danos & Mulligan, 1988 ) and collection of functional supernatant. As an empty vector control, pBabe-puro retrovirus was also produced by packaging the original pBabe-puro vector into the y-crip packaging cell line. Retroviral infection of EBV-transformed LCLs was performed using an adaptation of a previously described method (Tonks et al., 2005) . Retrovirally transduced LCLs were then selected using 1 mg puromycin ml 21 .
SDS-PAGE and Western blotting. SDS-PAGE and Western blotting were performed as described by McLaren et al. (2007) and Rowe & Jones (2001) . Semiquantitative measurements of Western blots were performed by densitometry using the Gene Tools software (GRI). The antibodies used for experiments are given in Table 1 . The EE serum was obtained from a patient exhibiting high titres of antibodies to several early and late lytic cycle antigens (Rowe et al., 1992) .
Flow cytometric analysis of cell surface antigens. The monoclonal antibodies (mAbs) W6/32 and L243 (ATCC) were used for the flow cytometric detection of cell surface MHC class I (HLA-A, -B and -C alleles) and MHC class II (HLA-DR), respectively. Fluorescein isothiocyanate (FITC)-conjugated mAbs specific for CD54 (MCA1615F) and CD19 (MCA1940F) were purchased from Serotec. Flow cytometric analysis of cell surface antigens was performed as described previously (Pappworth et al., 2007) .
LCL recognition assays involving EBV-specific CD8 + T cell clones. For LCL recognition assays, EBV-specific CD8 + T cell clones to the following epitopes were used: HLA-B35 restricted EBNA1 407-417 HPV (Blake et al., 1997) and HLA-A11 restricted EBNA3B 399-408 AVF (Gavioli et al., 1993) . Each T cell clone was incubated at 37 uC in V-bottom 96-well plates with LCL targets, and the supernatants were harvested 18 h post-incubation for analysis by ELISA of IFN-c release (Long et al., 2005) .
Quantitative RT-PCR assays specific for EBV gene transcripts.
Quantitative RT-PCR assays were used to detect Wp-and Cpinitiated transcripts, QUK-and YUK-spliced EBNA1 mRNA, EBNA2, LMP1 and LMP2A mRNAs, Fp-initiated (FQUK-spliced) lytic transcripts and BZLF-1 mRNA using a previously described method (Bell et al., 2006) .
Induction of EBV lytic cycle in AKBM cells. The EBV + AKBM cell line displays a strictly non-productive infection but a subpopulation can be induced into the lytic cycle by ligation of cell surface IgG with 100 mg goat anti-human IgG antibody ml 21 (Cappel). At 24 h postligation, the cells in the lytic cycle were isolated by immuno-magnetic sorting for the rat-CD2/GFP reporter as described previously (Ressing et al., 2005) . Non-induced AKBM cells were used as a control and were mock-sorted under the same conditions as lytically induced AKBM cells.
RESULTS

Generation of an in vitro model to study the function of STAT1 in EBV-transformed LCLs
In order to study the functional role of STAT1 in EBVtransformed LCLs, we used the SV5 V-protein to specifically downregulate STAT1 expression in these cells. The introduction of the SV5 V-protein into EBV-transformed LCLs has been attempted before using adenoviral technology (Richardson et al., 2005) . However, although a small reduction in STAT1 protein expression was observed, the effects were transient and required an EBV-transformed LCL that was engineered to be more susceptible to adenoviral infection (Richardson et al., 2005) . In order to introduce the SV5 V-protein more permanently, retroviral infection was chosen. The SV5 V-protein was cloned into the pBabe-puro retroviral vector (Morgenstern & Land, 1990) and was used to retrovirally infect two EBVtransformed LCLs, IARC-171 and IB4. These transduced LCLs, termed IARC-171 and IB4 V-protein LCL, were analysed for the expression of a panel of STATs (STAT1, STAT3 and STAT5) by Western blotting. Two empty vector controls, IARC-171 and IB4 pBabe LCL, were generated following retroviral infection with an empty vector retrovirus. IARC-171 and IB4 V-protein LCLs displayed a considerable reduction in STAT1 protein expression ( Fig. 1a ), quantified by densitometry ( Fig. 1b ), which correlated with the presence of the SV5 V-protein.
No effect was seen on STAT3 and STAT5 protein expression, which verified the STAT1-specific V-protein phenotype. A greater reduction in STAT1 protein expression was seen in the IARC-171 V-protein LCL compared with the IB4 V-protein LCL, reflecting the relative expression of the SV5 V-protein in these cells. It has been demonstrated that the degradative effects of the SV5 Vprotein on STAT1 can be reversed by using the proteasome inhibitor MG132 (Didcock et al., 1999) . To determine whether the V-protein phenotype could be reversed in IARC-171 V-protein LCL, cells were incubated with or without MG132 (10 or 20 mM) for 1 h before analysing STAT1 protein expression. The V-protein phenotype was reversed by MG132 ( Fig. 1c ), restoring STAT1 protein levels to those seen with IARC-171 pBabe LCL. These data demonstrate that both sets of pBabe (control) and Vprotein LCLs represent a cellular model for studying the function of STAT1 in EBV-transformed LCLs. Cell surface expression of the MHC and adhesion molecules are downregulated following knockdown of STAT1 protein expression
The immune control exhibited by circulating CTLs on EBV-transformed B cells in immunocompetent hosts is crucially dependent on the high levels of surface MHC class I molecules and adhesion molecules found on these cells (Rickinson & Moss, 1997) . Both MHC class I molecules and CD54 (ICAM-1) are upregulated during EBV transformation by LMP1 Wang et al., 1988) . MHC class I molecules also display an absolute requirement for STAT1 in IFN-stimulated responses (Meraz et al., 1996; Müller et al., 1993) . In addition to this, STAT1 is also involved in the constitutive expression of MHC class I molecules in T cells (Lee et al., 1999) . Since STAT1 is also upregulated by LMP1 (Richardson et al., 2003; Zhang et al., 2004) , we next investigated whether STAT1 was involved in maintaining the levels of surface MHC class I observed on EBV-transformed LCLs. Using both sets of pBabe and Vprotein LCLs, we compared MHC class I cell surface expression by flow cytometry (Fig. 2a ). This clearly shows a downregulation of MHC class I cell surface expression in both V-protein LCLs compared with their controls. We next examined whether the expression of other cell surface markers, such as MHC class II, were similarly downregulated in the V-protein LCLs. Cell surface expression of MHC class II and the adhesion molecule CD54, but not CD19, were also downregulated in the V-protein LCLs (Fig. 2a ).
The collective results of four experiments for all four cell surface markers are summarized in Fig. 2(b and c) . In the IARC-171 V-protein LCL, expression of surface MHC class I and class II was reduced by 42 and 58 %, respectively, compared with IARC-171 pBabe LCL. CD54 expression was reduced by 51 %, whereas CD19 expression actually increased by 40 %. In the IB4 V-protein LCL, expression of surface MHC class I and class II was reduced by 20 and 43 %, respectively, compared with IB4 pBabe LCL. CD54 expression was reduced by 24 %, whereas CD19 expression stayed the same. All the differences in cell surface expression were statistically significant (P,0.05). Interestingly, the reduction in MHC class I, MHC class II and CD54 cell surface expression was more prominent in the IARC-171 V-protein LCL than in the IB4 line, reflecting the relative expression of STAT1 in these lines. In addition to MHC class I and adhesion molecules, components of the antigen processing machinery, such as the TAP-1 and TAP-2 peptide transporter proteins, are also upregulated by LMP1 . Furthermore, IFN-regulated components of the proteasome, such as the low-molecular weight protein-2 are regulated by both STAT1 and IFN-regulatory factor-1 (IRF-1) (Chatterjee-Kishore et al., 2000); IRF-1 has also been implicated in inducing MHC class I expression (Chang et al., 1992; Hobart et al., 1997; Lee et al., 1999) . We therefore questioned whether the downregulation of MHC class I cell surface expression on V-protein LCLs might reflect an impairment of the antigen processing machinery or a specific reduction in MHC class I heavy chain protein expression. To address this question, we used Western blotting to analyse the protein levels of MHC class I, IRF-1, TAP1, TAP2 and low-molecular weight protein-2 in both sets of pBabe and V-protein LCLs. Levels of MHC class I, IRF-1 and TAP2 were substantially reduced in the Vprotein LCLs, while TAP-1 showed a small but reproducible reduction, and low-molecular weight protein-2 remained unaffected by V-protein (Fig. 2d) . These data suggest that the synthesis of MHC class I molecules and other components of the antigen processing machinery are impaired, and explain why MHC class I cell surface expression is downregulated in the V-protein LCLs.
STAT1 can regulate the recognition of LCLs by cytotoxic T cells
EBV-transformed B cells are good targets for recognition by circulating EBV-specific CTLs due to the high expression of cell surface MHC class I molecules (Rickinson & Moss, 1997) . The results in Fig. 2 suggest that this recognition is impaired by the V-protein through its multiple effects on the MHC class I antigen presentation pathway and on the expression of adhesion molecules necessary for efficient CTL-target binding. To test this hypothesis, we compared the recognition of IARC-171 pBabe and V-protein LCLs by EBV-specific CD8 + CTLs using an ELISA for IFN-c released by T cells that gives a quantitative measurement of the T cell recognition of the EBV + target cells (Long et al., 2005) . This assay was only performed on IARC-171 pBabe and V-protein LCLs as they demonstrated the biggest difference in MHC class I cell surface expression ( Fig. 2 ) and the HLA-type was matched to two available T cell clones: HPV (Blake et al., 1997) and AVF (Gavioli et al., 1993) . The number of T-cells was kept the same for each assay and different numbers of LCLs were seeded to give a range of effector : target ratios. Culture supernatants were harvested from co-cultures of the LCL targets and T-cell clones after 18 h at 37 u C, and were then assayed for IFN-c release. Fig. 3 shows results from a representative experiment for each of the two T-cell clones. Controls were performed to verify the specificity of the effector T cells. These included T-cell clones incubated alone and T cells incubated with HLA matched or mismatched LCLs (with or without previous exposure to 5 mM epitope peptide) (data not shown). Since IFN-c release from LCLs has been demonstrated to be modest (,1 pg ml 21 ) (Najjar et al., 2005) , the changes in IFN-c release reflect those from the effector T cells. The IARC-171 V-protein LCL was recognized less well by both EBVspecific CD8 + T cells compared with the IARC-171 pBabe LCL (Fig. 3) . In both assays, the differences in recognition were statistically significant and confirm our hypothesis that downregulation of STAT1 expression in EBV-transformed LCLs impairs their recognition by EBV-specific CD8 + T cells.
STAT1 represses LMP2A expression
There is some evidence that STATs and IRF-1 are involved in regulating not only cellular genes but also EBV latent genes (Chen et al., 1999 (Chen et al., , 2001 Schaefer et al., 1997) . Considering this, we investigated whether the expression of EBV latent genes differed between pBabe and V-protein LCLs. To do this, we first analysed the protein expression of a panel of EBV latent genes (LMP-1 and -2 and EBNA1, -2, -3A, -3B and -3C) in both sets of pBabe and V-protein LCLs by Western blotting. The expression of LMP1 and the EBNAs tested does not alter between pBabe and V-protein LCLs (Fig. 4a ). IB4 LCL, which has been reported previously to be an EBNA3B-negative mutant LCL (King et al., 1980) , displayed a truncated form of EBNA3B, which is consistent with a recent report (Chen et al., 2005) . In contrast with the other latent proteins, expression of LMP2A differed markedly between the two IARC-171 clones, being more highly expressed in the V-proteinexpressing cells (Fig. 4a) . No LMP2A protein, however, was found in either of the IB4 cell lines, despite the detection of LMP2A transcripts by qRT-PCR (Fig. 4b ). However, IB4 contains four or five integrated copies of the genome, some of which disrupt the LMP2A gene to yield truncated transcripts that would still be detected by the qRT-PCR assay (Takakuwa et al., 2005) . This cell line is, therefore, not well-suited to analysing the effects on LMP2A expression. To verify the generality of the effect on LMP2A expression in the IARC-171 LCL, we generated pBabe and V-protein clones from three additional newly established LCLs and analysed their LMP2A protein expression. The expression of LMP2A was consistently higher in the V-protein clones compared with their pBabe counterparts, and the V-protein clones had reduced levels of STAT1 (Fig. 4c ).
Since the Western blot data would not necessarily detect altered promoter activity for the EBNA transcripts, we performed qRT-PCR assays (Bell et al., 2006) to quantitatively assay Wp-, Cp-and Qp-initiated EBNA transcripts (Fig. 4b) . These transcripts did not differ between pBabe and V-protein clones within each line although, as expected, there were marked differences between the IARC-171 and IB4. Whereas IB4 exclusively utilized Wp, owing to a deletion in the Cp region (Sample et al., 1986) , the IARC-171 utilized both the Wp and Cp promoters. QUK-spliced EBNA1 mRNA was not observed in all LCLs, since EBNA1 is transcribed from Wp/Cp promoters in latency III instead of being transcribed from the Qp promoter, as seen in BL cell lines (Kelly et al., 2002; Nonkwelo et al., 1996; Schaefer et al., 1995) . LMP1 mRNA expression did not really change in either of the V-protein LCLs but there was a twofold increase in LMP2A mRNA expression in the IARC-171 V-protein LCL compared with pBabe, which agreed with the protein expression data. Together, these data suggest that the main effect of STAT1 on the latent EBV genome is to repress LMP2A expression.
STAT1 regulates spontaneous EBV lytic cycle gene expression
The data in Fig. 2 demonstrate that MHC class I and class II cell surface expression is downregulated in V-protein LCLs. A similar downregulation has also been described for cells that enter EBV lytic cycle (Keating et al., 2002) . Induction of the lytic cycle is critically dependent on the expression of the immediate-early antigen BZLF-1 . BZLF-1 has been shown to impede the ability of LMP1 to upregulate cell surface MHC class I molecules (Keating et al., 2002) and the early lytic cycle genes BNLF2a and BGLF5 have been shown to reduce surface expression of MHC molecules by different mechanisms (Hislop et al., 2007; Rowe et al., 2007) . Since a number of EBV-transformed LCLs consistently have a small population of cells (less than 5 %) that are spontaneously lytic , we investigated the hypothesis that STAT1 regulates the expression of lytic cycle genes such as BZLF-1.
To test this hypothesis we first measured BZLF-1 and STAT1 protein expression by Western blotting in both sets of pBabe and V-protein LCLs. Owing to the integrated viral genomes in IB4, this cell line cannot be induced into the lytic cycle (King et al., 1980) , and both IB4 lines were completely negative for BZLF-1 protein (Fig. 5a ). In the IARC-171 lines, however, expression of BZLF-1 was markedly higher in the V-protein LCL compared with the pBabe LCL. The V-protein phenotype in the IARC-171 V-protein LCL was reversed by incubation of the cells with MG132, which restored STAT1 expression and concomitantly reduced BZLF-1 expression (Fig. 5c ). This suggests that STAT1 can repress spontaneous BZLF-1 expression. Consistent with this interpretation, the expression of BZLF-1 mRNA, along with Fp-initiated lytic EBNA1 transcripts was found to be 10-fold higher in the IARC V-protein LCL compared with the pBabe LCL (Fig.  5b ). Although this increase in lytic transcripts was large, the expression of these transcripts is still low, since a value of 1 corresponds to an LCL with about 5 % of cells spontaneously in lytic cycle. Western blots of the IARC-171 pBabe and V-protein lines probed with EE serum indicated that there was an increase in the expression of other early antigens, part of the EA (D) complex (Fig. 5d ). These data demonstrate that more cells are entering the lytic cycle in IARC-171 V-protein LCL compared with pBabe LCL.
The data in Fig. 5 has thus far indicated that STAT1 can repress the spontaneous expression of EBV lytic cycle genes. We next investigated whether latently infected B cells that have been induced to differentiate and enter the lytic cycle might show reduced levels of STAT1. To test this, we induced the Akata-derived AKBM reporter lines by ligating the B-cell receptor, and isolated a population of cells in the lytic cycle (Ressing et al., 2005) . Total lysates from the isolated cells and uninduced control AKBM cell lysates were analysed for STAT1, BZLF-1 and BGLF-5 protein expression by Western blotting. Fig. 5 (e) shows that successful induction of the lytic cycle in AKBM cells was accompanied by a 40 % reduction in STAT1 protein levels. Overall, the data in Fig. 5 are consistent with the hypothesis that STAT1 contributes to the repression of lytic cycle genes in latently infected B cells, and that successful induction of lytic cycle may first require a reduction in STAT1 expression or function.
DISCUSSION
This study provides new evidence for a role for STAT1 in EBV biology. Using a novel strategy to specifically reduce STAT1 protein expression in EBV-transformed LCLs, we have shown that STAT1 contributes to the high levels of cell surface expression of MHC class I and II molecules found on these cells. In addition, we have shown that other members of the MHC class I antigen processing machinery, like TAP1 and TAP2, are regulated by STAT1. These effects correlate with their recognition by EBV-specific cytotoxic T cells and suggest that STAT1 aids viral peptide presentation and renders these cells more recognizable to the host EBV immunosurveillance. This role is compatible with the model proposed by Le Clorennec et al. (2006) , who showed that induction of CD95 expression by EBV, through STAT1, plays a key role in the immune control of EBVtransformed B-cells in vivo. The ability of EBV-specific CTLs to recognize proliferating, latency III EBV-transformed B cells is crucial to the establishment of a host- virus equilibrium and a lifelong management of EBV infection, as evidenced by the increased incidence of PTLD in immunosuppressed individuals (Tanner & Alfieri, 2001) . As a result, it seems that EBV uses STAT1 to establish the host-virus equilibrium seen in immunocompetent hosts.
Whilst a reduction in STAT1 expression correlated with a 10-fold increase in lytic transcripts, it should be noted that the actual percentage of cells entering the lytic cycle remained very low. Therefore, although the lytic cycle is associated with an inhibition of cell surface MHC and adhesion molecule expression (Keating et al., 2002) , this alone cannot explain the global effect on cell surface phenotype within cultures of LCLs with reduced STAT1 expression. However, the demonstration that STAT1 can repress the expression of lytic transcripts highlights a potential requirement for EBV to downregulate STAT1 in order to replicate. This hypothesis is supported by the fact that the lytic SM protein has been shown to induce alternative STAT1 mRNA splicing leading to STAT1b overproduction, which antagonizes the active STAT1a and, therefore, downregulates STAT1 activity (Verma & Swaminathan, 2008) . Thus, STAT1, which is a key mediator of the antiviral IFN response, may also be a limiting factor for EBV replication.
While the majority of EBV latent genes are not regulated by STAT1, we found that LMP2A expression was increased in V-protein LCLs (Fig. 4) . Interestingly, it has been reported that LMP2A can induce EBV-infected B cells into the lytic cycle in the absence of lytically inducing stimuli such as anti-IgG (Schaadt et al., 2005) . Therefore, the upregulation of LMP2A may contribute to the increased activation of the lytic cycle in V-protein LCLs (Fig. 5) . Although a mechanism for this phenotype was not investigated, it is plausible that STAT1 may form a repressive complex in the LMP2A promoter and thus limit transcription. This is supported by evidence that shows that the Qp promoter and two LMP1 promoters contain putative STAT binding sites (Chen et al., 1999 (Chen et al., , 2001 . However, a search for transcription factor binding sites within the LMP2A promoter indicated a lack of putative STAT binding sites, and a recent study showed that only CBF-1, Sp1 and CCAAT binding sites were found in the promoter (Salamon et al., 2003) . Considering this, it is possible that the change in LMP2A expression in the V-protein cells may not result from a lack of direct binding of the LMP2A promoter by STAT1 but rather from a more indirect mechanism. Overall, it seems that STAT1 may help maintain a strict latency III phenotype in transformed B cells and contribute to the balance of the host-virus equilibrium, since EBV-infected cells in the lytic cycle are able to evade the host immunosurveillance.
We have shown previously that EBV induces a unique form of DNA-bound STAT1 in EBV-transformed LCLs that is constitutively serine phosphorylated (McLaren et al., 2007) . The present study demonstrates a role for STAT1 in repressing some latent and lytic EBV transcripts and in the immunorecognition of transformed B cells. The extent that the constitutive serine phosphorylation of STAT1 is integral to these roles remains to be determined.
In conclusion, this study proposes a model whereby EBV induces STAT1 expression in transformed B cells in order to help maintain viral latency in these cells and to help their recognition by the host EBV-specific immunosurveillance.
